- Psyence (PSYG) and Filament Health have signed an exclusive licensing agreement
- Filament will license its proprietary botanical drug candidate PEX010 and the associated IP to Psyence for use in upcoming palliative care clinical trials
- Dr. Neil Maresky, CEO of Psyence sat down with Shoran Devi to discuss the partnership with Filament
- Filament Health (FH) is a clinical-stage natural psychedelic drug development company
- Psyence is a public life science biotechnology company with a focus on natural psychedelics
- Psysence Group Inc. (PSYG) opened trading at C$0.10 per share
Psyence (PSYG) and Filament Health (FH) have signed an exclusive licensing agreement.
Under the terms of the agreement, Filament will license its proprietary botanical drug candidate PEX010 and the associated IP to Psyence for use in Psyence’s upcoming clinical trials.
The license grants Psyence exclusivity in the United Kingdom for the indications of anxiety and depression, and associated ailments, within the context of palliative care. Psyence intends to submit a clinical trial application (CTA) to the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom.
Dr. Neil Maresky, CEO of Psyence sat down with Shoran Devi to discuss the partnership with Filament.
“Filament is a global leader in the extraction and standardization of pharmaceutical-grade psychedelic botanical drug candidates.
Partnering with Filament is a perfect complement to our expertise in both the cultivation and delivery of these substances to patients in need as we commence our palliative care clinical trial. Licensing Filament’s IP and leveraging their data and experience will allow us to expedite our UK clinical trial application.”
Psyence is also preparing to export its mushrooms to Filament. Filament will process the raw material and manufacture a dosage form for use in future clinical trials. Psyence’s psilocybin mushrooms are cultivated at its licensed production facility in Southern Africa.
PEX010 is Filament’s proprietary botanical drug candidate standardized to provide 25 mg of psilocybin per oral capsule and has previously received authorization from the FDA and Health Canada to enter into phase 1 and phase 2 human clinical trials.
Filament Health (FH) is a clinical-stage natural psychedelic drug development company.
Psyence is a public life science biotechnology company with a focus on natural psychedelics. Psyence works with natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care.
Psysence Group Inc. (PSYG) opened trading at C$0.10 per share.